Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Sayle KL, Mesguishe V, Parsons RJ, Bentley J, Davies TG, Endicott JA, Noble MEM, Wang LZ, Hardcastle IR, Golding BT. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. In: European Journal of Cancer: 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 2002, Frankfurt, Germany: Pergamon.
• Paleri V, Wight RG. A cross-comparison of retrospective notes extraction and combined notes extraction and patient interview in the completion of a comorbidity index (ACE-27) in a cohort of United Kingdom patients with head and neck cancer. Journal of Laryngology and Otology 2002, 116(11), 937-941.
• Moorman AV, Roman E, Cartwright RA, Morgan GJ. Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia. British Journal of Cancer 2002, 86(7), 1061-1063.
• Chilton L, Boulton AJM, Brieslin K, Tomlinson DR. An early blood test for diabetic neuropathy?. In: 62nd American Diabetes Association Annual Meeting. 2002, San Francisco, SA.
• Paleri V, Wight RG. Applicability of the adult comorbidity evaluation-27 and the Charlson indexes to assess comorbidity by notes extraction in a cohort of United Kingdom patients with head and neck cancer: a retrospective study. Journal of Laryngology and Otology 2002, 116(3), 200-205.
• Hollick JJ, Golding BT, Griffin RJ, Hardcastle IR, Leahy JJJ, Martin N, Rigoreau L, Smith GCM, Stockley ML. Application of combinatorial chemistry for the identification of pyran-4-one and thiopyran-4-one inhibitors of DNA-dependent protein kinase. In: 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 2002, Frankfurt, Germany: European Journal of Cancer: Pergamon.
• Lusher ME, Lindsey JC, Latif F, Pearson ADJ, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Research 2002, 62(20), 5906-5911.
• Raynaud FI, Smith NF, Griffin RJ, Hardcastle IR, Rigoreau LJM, Stockley ML, Leahy JJJ, Golding BT, Smith GC, Workman P. Cassette dosing iv and ip of novel DNA dependent protein kinase inhibitors. In: 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 2002, Frankfurt, Germany: European Journal of Cancer: Pergamon.
• Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133 as a putative prostatic epithelial stem cell marker. In: The British Prostate Group Collaborative Executive Meeting. 2002.
• West, K. L., Turnbull, R. M., Willmore, E., Lakey, J. H., Austin, C. A. Characterisation of the DNA-dependent ATPase activity of human DNA topoisomerase IIß: mutation of Ser165 in the ATPase domain reduces the ATPase activity and abolishes the in vivo complementation ability. Nucleic Acids Research 2002, 30(24), 5416-5424.
• Griffin RJ. Combinatorial methods for identifying antitumour kinase inhibitors. In: European Journal of Cancer: 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics. 2002, Frankfurt, Germany: Pergamon.
• Nouman, G., Angus, B., Lunec, J., Crosier, S, Lodge, A.J., Anderson, J.J. Comparative assessment expression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybridoma and Hybridomics 2002, 21(1), 1-10.
• Gasmi A, Bourcier C, Aloui Z, Srairi N, Marchetti S, Gimond C, Wedge SR, Hennequin LF, Pouysségur J. Complete structure of an Increasing Capillary Permeability Protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via VEGF receptor signaling. Journal of Biological Chemistry 2002, 277(33), 29992-29998.
• Northen J, Boyle F, Clegg W, Curtin NJ, Edwards A, Griffin R, Golding B. Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines. Journal of the Chemical Society. Perkin Transactions 1 2002, 2(1), 108-115.
• Doerig C, Endicott J, Chakrabarti D. Cyclin-dependent kinase homologues of Plasmodium falciparum. International Journal for Parasitology 2002, 32(13), 1575–1585.
• Hardcastle IR, Golding BT, Griffin RJ. Designing inhibitors of cyclin-dependent kinases. Annual Review of Pharmacology and Toxicology 2002, 42, 325-348.
• Lamb P, Dresner S, Karat D, Hayes N, Griffin SM. Diagnosis and management of a mediastinal leak following radical oesophagectomy (Br J Surg 2001; 88: 1346-51) - Reply. British Journal of Surgery 2002, 89(6), 811.
• Monks, N., Blakey, D., East, S., Dowell, R., Calvete, J., Curtin, N.J., Arris, C.E., Newell, D.R. DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767. European Journal of Cancer 2002, 38(11), 1543-1552.
• Griffin SM, Shaw IH, Dresner SM. Early complications after Ivor Lewis subtotal esophagectomy with two-field lymphadenectomy: Risk factors and management. Journal of the American College of Surgeons 2002, 194(3), 285-297.
• Lamb PJ, Dresner SM, Immanuel A, Robinson S, Irving M, Hayes N, Raimes SA, Griffin SM. Early postoperative intraperitoneal chemotherapy (EPIC) for gastric carcinoma - a prospective study. British Journal of Surgery 2002, 89(s1), 87.
• Maxwell RJ, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, Tozer GM, Wilson J. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR in Biomedicine 2002, 15(2), 89-98.
• Willmore, E., Errington, F., Tilby, M.J., Austin, C.A. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochemical Pharmacology 2002, 63(10), 1807-1815.
• Lovat, P.E., Oliverio, S., Ranalli, M., Corazzari, M., Rodolfo, C., Bernassola, F., Aughton, K., Maccarrone, M., Campbell-Hewson, Q., Pearson, A.D.J., Melino, G., Piacentini, M., Redfern, C.P.F. GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Research 2002, 62(18), 5158-5167.
• Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright PA, Morgan GJ, Wild CP. Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. British Journal of Haematology 2002, 116(3), 587-594.
• Allum WH, Griffin SM, Watson A, Colin-Jones D, Assoc Upper Gastrointestinal Surg. Guidelines for the management of oesophageal and gastric cancer. Gut 2002, 50(s2), 1-23.
• Ismail Y, McLean NR, Kelly CG. Head and neck oncology: the UK experience. Who is publishing what?. British Journal of Plastic Surgery 2002, 55(7), 570-573.
• Smith NF, Raynaud FI, Griffin RJ, Hardcastle IR, Rigoreau LJM, Stockley ML, Leahy JJJ, Golding BT, Martin N, Smith GCM, Workman P. High throughput pharmacokinetics of novel DNA-dependent protein kinase inhibitors. In: British Cancer Conference. 2002, Glasgow, UK: British Journal of Cancer: Nature Publishing Group.
• Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Research 2002, 62(13), 3803-3811.
• Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. Identification of differentially-expressed genes in the stem cells and transit amplifying compartments of prostatic epithelia by microarray. In: The British Prostate Group Collaborative Executive Meeting. 2002.
• Paleri V, Robson AK. Impact of surgical approaches and antimetabolite use on the outcome of dacryocystorhinostomy for lacrimal obstruction: a meta analysis. Annals of the Royal College of Surgeons of England 2002, 84(5), 362-362.
• Plummer CJ, Irving RJ, McComb JM. Implications of national guidance on the implantation of implantable cardioverter-defibrillators for arrhythmias. In: European Heart Journal: Congress of the European Society of Cardiology. 2002, Berlin, Germany: Oxford University Press.
• Veal, G. J., Errington, J., Redfern, C., Pearson, A. D. J., Boddy, A. V. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology 2002, 63(2), 207-215.
• Wang XN, Lange C, Schulz U, Sviland L, Eissner G, Oliver KM, Jackson GH, Holler E, Dickinson AM. Interleukin-10 modulation of alloreactivity and graft-versus-host reactions. Transplantation 2002, 74(6), 772-778.
• Redfern, C.P.F., Douglas, G., Halliday, T. Intestine length and mass relative to fat in migrating Redwings Turdus iliacus. Ardea 2002, 90(2), 285-292.
• Moorman AV, Richards S, Harrison CJ. Involvement of the MLL gene in T-lineage acute lymphoblastic leukaemia. Blood 2002, 100(6), 2273-2273.
• Clifford SC, Arndt SK, Popp M, Jones HG. Mucilages and polysaccharides in Ziziphus species (Rhamnaceae): localization, composition and physiological roles during drought-stress. Journal of Experimental Botany 2002, 53(366), 131-138.
• English C, Brown J, Drewery C, Hellens SW, Schwab CJ, White J, Wright C. Multiple structurally abnormal cell lines involving the same chromosome breakpoint: two cases detected by chorion villus biopsy. In: Journal of Medical Genetics: British Human Genetics Conference. 2002, York: BMJ Group.
• Bailey, S., Roberts, A., Brock, C., Price, L., Craft, A. W., Kilkarni, R., Lee, R. E. J., Skillen, A. W., Skinner, R. Nephrotoxicity in survivors of Wilms' tumours in the North of England. British Journal of Cancer 2002, 87(10), 1092-1098.
• Tomlinson DR, Chilton L. Neurotrophin Receptor p75 as a plasma marker for Diabetic Neuropathy. In: 38th Annual Meeting of the European Association of the Study of Diabetes. 2002, Budapest, Hungary.
• Chilton L, Tomlinson DR. Neurotrophin Receptor p75 as a plasma marker for Diabetic Neuropathy. In: Society for Neuroscience Meeting. 2002, Orlando, Florida.
• Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry 2002, 45(6), 1300-1312.
• Koch SSC, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li JK, Yu XH, Zook SE, Kumpf RA, Zhang C, Boritzki TJ, Mansour RN, Zhang KE, Ekker A, Calabrese CR, Curtin NJ, Kyle S, Thomas HD, Wang LZ, Calvert AH, Golding BT, Griffin RJ, Newell DR, Webber SE, Hostomsky Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure. Journal of Medicinal Chemistry 2002, 45(23), 4961-4974.
• Nouman G, Anderson JJ, Mathers ME, Leonard N, Crosier S, Lunec J, Angus B. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology 2002, 40(4), 360-366.
• Immanuel A, Lamb PJ, Robinson S, Karat D, Hayes N, Griffin SM. Oesophago-gastric stromal tumours: a single unit experience. British Journal of Surgery 2002, 89(s1), 27.
• Stewart GD, Watson AJM, Lamb PJ, Lee AJ, Krukowski ZH, Griffin SM, Paterson-Brown S. Outcome after antireflux surgery - a comparison between open Nissen, laparoscopic Nissen and laparoscopic Watson fundoplications. British Journal of Surgery 2002, 89(s1), 26.
• Nouman GS, Anderson JJ, Crosier S, Shrimankar J, Lunec J, Angus B. p33^ING1b tumour suppressor immunohistochemical expression in invasive breast carcinomas. In: 184th Meeting of The Pathological Society of Great Britain and Ireland. 2002, Trinity College, Dublin, Ireland: Journal of Pathology: John Wiley & Sons Ltd.
• Moorman AV, Roman E, Cartwright RA, Morgan GJ. Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK. Clinical and Laboratory Haematology 2002, 24(4), 263-265.
• Chandrashekar MV, Richardson DL, Preston S, Karat D, Griffin SM. Perforation of a nonobstructing gastro-oesophageal carcinoma by oblique-viewing endoscopic ultrasound videoscope: A need for a safe technique. Endoscopy 2002, 34(11), 934-934.
• Plummer ER, Ghielmini M, Calvert PM, Voi M, Renard J, Gallant G, Gupta E, Calvert AH, Sessa C. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clinical Cancer Research 2002, 8(9), 2788-2797.
• Hughes AN, Calvert PM, Azzabi A, Plummer ER, Johnson R, Rusthoven J, Griffin MJ, Fishwick KA, Boddy AV, Verrill MW, Calvert AH. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Journal of Clinical Oncology 2002, 20(16), 3533-3544.
• Batey MA, Wright JG, Azzabi A, Newell DR, Lind MJ, Calvert AH, Boddy AV. Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European Journal of Cancer 2002, 38(8), 1081-1089.
• Immanuel A, Lamb PJ, Wayman J, Preston S, Griffin SM. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. British Journal of Surgery 2002, 89(5), 626.
• Gibson A, Arris CE, Bentley J, Boyle F, Curtin NJ, Davies T, Endicott J, Golding BT, Grant S, Griffin R, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J., Whitfield, H.J. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives. Journal of Medicinal Chemistry 2002, 45(16), 3381-3393.
• Lamb PJ, Immanuel A, Lloyd J, Richardson DL, Wilsdon J, Karat D, Hayes N, Griffin SM. Prospective evaluation of bone scintigraphy as a staging investigation for oesophageal carcinoma. British Journal of Surgery 2002, 89(s1), 26.
• Thomas HD, Porter D, Bartelink I, Nobbs J, Cole M, Elliott S, Newell DR, Calvert AH, Highley M, Boddy AV. Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide. British Journal of Clinical Pharmacology 2002, 53(1), 83-91.
• Campbell-Hewson, Q., Lovat, P.E., Pearson, A.D.J., Redfern, C.P.F. Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARβ expression. Journal of Cellular Biochemistry 2002, 87(3), 284-291.
• Rana B, Veal GJ, Pearson ADJ, Redfern CPF. Retinoid X receptors and retinoid response in neuroblastoma cells. Journal of Cellular Biochemistry 2002, 86(1), 67-78.
• Leng XH, Noble M, Adams PD, Qin J, Harper JW. Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Molecular and Cellular Biology 2002, 22(7), 2242-2254.
• Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. British Journal of Haematology 2002, 118(4), 1071-1077.
• Jagoe, R.T., Redfern, C.P.F., Roberts, R.G., Gibson, G.J., Goodship, T.H.J. Skeletal muscle mRNA levels for cathepsin B, but not components of the ubiquitin-proteasome pathway, are increased in patients with lung cancer referred for thoracotomy. Clinical Science 2002, 102(3), 353-361.
• Moorman AV, Roman E, Cartwright RA, Morgan GJ. Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. British Journal of Cancer 2002, 86(1), 60-62.
• Roberts, R.G., Redfern, C.P.F., Graham, K.A., Bartlett, K., Wilkinson, R., Goodship, T.H.J. Sodium bicarbonate treatment and ubiquitin gene expression in acidotic human subjects with chronic renal failure. European Journal of Clinical Investigation 2002, 32(7), 488-492.
• Lowe ED, Tews I, Cheng KY, Brown NR, Gul S, Noble MEM, Gamblin SJ, Johnson LN. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 2002, 41(52), 15625-15634.
• Paleri V, Maroju RS, Ali MS, Ruckley RW. Spontaneous retro- and parapharyngeal haematoma caused by intrathyroid bleed. Journal of Laryngology and Otology 2002, 116(10), 854-858.
• Johnson LN, DeMoliner E, Brown NR, Song HW, Barford D, Endicott JA, Noble MEM. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. In: Pharmacology & Therapeutics: 2nd International Confernce on Inhbitors of Protein Kinases. 2002, Warsaw, Poland: Elsevier Inc.
• Davies T, Bentley J, Arris CE, Boyle FT, Curtin NJ, Endicott J, Gibson A, Golding BT, Griffin RJ, Hardcastle IR, Jewsbury, P., Johnson, L., Mesguiche, V., Newell, D.R., Noble, M., Tucker, J.A., Wang, L., Whitfield, H.J. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nature Structural Biology 2002, 9(10), 745-749.
• Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble MEM. Structure-based design of cyclin-dependent kinase inhibitors. In: Pharmacology & Therapeutics: 2nd International Confernce on Inhbitors of Protein Kinases. 2002, Warsaw, Poland: Elsevier Inc.
• Burroughs A, Rolles K, Gimson A, Jamieson N, Hudson M, Thick M, O'Grady J, Heaton N, Mayer D, Neuberger J, Macgilchrist A, Forsythe J, Davies M, Pollard S, McCormick A. Tacrolimus versus microemulsified cyclosporine in liver transplantation - The TMC randomised trial. Final results at one year. Journal of Hepatology 2002, 36(s1), 26 abstract no. 79.
• Jarvis M, Schulz U, Dickinson AM, Sviland L, Jackson G, Konur A, Wang XN, Hromadnikova I, Kolb HJ, Eissner G, Holler E. The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions. Journal of Clinical Pathology 2002, 55(2), 127-132.
• Coulthard, S.A., Hogarth, L.A., Little, M.A., Matheson, E., Redfern, C.P.F., Minto, C.L.J., Hall, A.G. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Molecular Pharmacology 2002, 62(1), 102-109.
• Prest SJ, May FEB, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. The FASEB Journal 2002, 16(2), 592-+.
• Edmondson R, Monaghan JM, Davies BR. The human ovarian surface epithelium is an androgen responsive tissue. British Journal of Cancer 2002, 86(6), 879-885.
• Lamb PJ, Wayman J, Billings M, Irving M, Karat D, Hayes N, Raimes SA, Griffin SM. The impact of new referral guidelines on delays in the diagnosis of oesophago-gastric cancer. Gut 2002, 50(s2), A45-A46 abstract no. 163.
• Burns, A.S.Y.W., Jaros, E., Cole, M., Perry, R., Pearson, A.D.J., Lunec, J. The molecular pathology of p53 in primitive neuroectodermal tumours of the central nervous system. British Journal of Cancer 2002, 86(7), 1117-1123.
• Sandy J, Mushtaq A, Kawamura A, Sinclair J, Sim E, Noble M. The structure of arylamine N-acetyltransferase from mycobacterium smegmatis - An enzyme which inactivates the anti-tubercular drug, Isoniazid. Journal of Molecular Biology 2002, 318(4), 1071-1083.
• Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., Robson, C. N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Journal of Biological Chemistry 2002, 277(29), 25904-25913.
• Simpson, A. B., Calvert, P. M., Sludden, J., Boddy, A. V., Griffin, M. J., Schatzlein, A., Wilson, P., Fishwick, K., Wheatley, A., Ross, G. A., Calvert, A. H., Twelves, C. J. Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Annals of Oncology 2002, 13(3), 399-402.
• Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM. Treatment of infants with lymphoblastic leukaemia. British Journal of Haematology 2002, 117(2), 306-314.
• Leung E, Shenton BK, Jackson G, Gould FK, Yap C, Talbot D. Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. Journal of Immunological Methods 2002, 270(2), 259-267.
• Ariffin R, Crosier S, Angus B, Anderson JJ. Use of transgenomic wave and denaturing gel electrophoresis increases the sensitivity of FR3A-FR4 PCR detection of B-cell clonality. In: 184th Meeting of The Pathological Society of Great Britain and Ireland. 2002, Trinity College, Dublin, Ireland: Journal of Pathology: John Wiley & Sons Ltd.
• Seddon BM, Maxwell RJ , Grimshaw R, Raynaud F, Tozer GM, Workman P, Honess DJ. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clinical Cancer Research 2002, 8(7), 2323-2335.
• Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 (“Iressa‟), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model. British Journal of Cancer 2002, 86(7), 1157-1161.
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Barnes C, Musgrove HL, Graham GA, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Hennequin LF. ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling and Growth of a Wide Range of Tumor Models Following Chronic Oral Administration. Cancer Research 2002, 62(16), 4645-4655.
• Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO. ZM323881, a novel inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase activity blocks VEGF-mediated increases in microvascular permeability in vivo. Microcirculation 2002, 9(6), 513-522.